Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Current Assets (2020 - 2025)

Historic Current Assets for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $86.8 million.

  • Barinthus Biotherapeutics' Current Assets fell 3555.26% to $86.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $86.8 million, marking a year-over-year decrease of 3555.26%. This contributed to the annual value of $125.7 million for FY2024, which is 1986.11% down from last year.
  • As of Q3 2025, Barinthus Biotherapeutics' Current Assets stood at $86.8 million, which was down 3555.26% from $100.4 million recorded in Q2 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Current Assets peaked at $256.7 million during Q2 2021, and registered a low of $86.8 million during Q3 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' median Current Assets value was $171.1 million (recorded in 2023), while the average stood at $175.1 million.
  • Per our database at Business Quant, Barinthus Biotherapeutics' Current Assets soared by 37340.35% in 2021 and then crashed by 3555.26% in 2025.
  • Quarter analysis of 5 years shows Barinthus Biotherapeutics' Current Assets stood at $226.8 million in 2021, then decreased by 6.05% to $213.0 million in 2022, then fell by 26.35% to $156.9 million in 2023, then fell by 19.86% to $125.7 million in 2024, then tumbled by 30.98% to $86.8 million in 2025.
  • Its last three reported values are $86.8 million in Q3 2025, $100.4 million for Q2 2025, and $109.9 million during Q1 2025.